Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Top review managers tell NORD conference they are eager to find ways to accelerate development and comercialization of orphan drugs. CDER’s Woodcock suggests new partnership models focused on translational researc h as key component. CBER’s Yetter notes flexibility of regulatory standards and creative ideas for trial design
You may also be interested in...
"Regulatory Predictability" Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
FDA's new leadership should focus on improving the "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 5
"Regulatory Predictability" Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
FDA's new leadership should focus on improving the "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 5
Venture Philanthropy Reaches Out To Biotechs
A sign of the times: The Michael J. Fox Foundation interviews 33 companies in the first two days of partnering talks at BIO.